Genetic Engineering News (GEN) has published 'The State of Biologics Testing 2026,' a collaborative report designed to inform discussion and decision-making within the biologics sector. The report aims to capture the collective voice of an industry navigating new scientific and regulatory challenges.
The report focuses on how biologics testing is adapting to emerging technologies and shifting oversight frameworks. It emphasizes that the document is intended to guide debate rather than prescribe specific solutions.
Regulatory pathways remain a central theme as companies face evolving requirements from agencies like the FDA and EMA. The report notes that the industry is responding to these changes with updated testing protocols and quality control measures.
GEN's report arrives amid broader trends in biotech toward more complex biologics, including gene therapies and cell therapies, which demand advanced analytical methods. The publication underscores the sector's need for harmonized standards and collaborative approaches.
While the report does not provide specific data or case studies, it serves as a strategic overview for stakeholders. Experts caution that without concrete benchmarks, translating these insights into actionable strategies may prove challenging.